Carey Anders on Muck Rack

Carey Anders

Durham, North Carolina
As seen in: Nature, Wiley, Wiley Online Library, Cancer Investigation, Medscape, The Lancet, HemOnc Today, Journal of Clinical Oncology, Future Medicine, ONCOLOGY journal and
Medical oncologist, Medical Director of the Duke Brain and Spine Metastases Center, Duke Cancer Institute, Durham, NC
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Carey

Contact Carey, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer

|
By Paolo Tarantino, Se-eun Kim, Melissa Hughes, Kalie Smith, Fara Brasó-Maristany, Laura Alder, Alyssa Pereslete, Heather Moore, Tianyu Li, Hersh V. Gupta, Stefania Morganti, Jennifer Spindel, Christine McLaughlin, Kathrin Dvir, Ana C. Garrido-Castro, Sarah L. Sammons, Simone Buck, Deborah R. Dillon, Rinath Jeselsohn, Yvonne Y. Li, Andrew D. Cherniack, Patricia LoRusso, Maryam B. Lustberg, Rosario León, Francisco Pardo, Justin Davis, Claudius Mueller, Giuseppe Curigliano, Carey Anders, Emanuel F. Petricoin, David Rimm, Aleix Prat, Nabihah Tayob, Nancy Lin, Sara M. Tolaney, Ross J. Kusmick, Laia Paré Brunet, Diana Garcia-Cortes, Laura Noteware, Amanda E. D. Van Swearingen, Olivia D’Amico, Alba Martini, Charmaine Cook, Kerry Sendrick, Brian Corgiat
| Nature Verified
Abstract Trastuzumab deruxtecan (T-DXd) is commonly used for treating metastatic breast cancer (MBC); however, traditional HER2 immunohistochemistry has largely failed to predict T-DXd activity. We reviewed survival outcomes and tested the reliability of multiple HER2 quantitative assays in predicting T-DXd’s performance among 191 patients with MBC.
Open in Who Shared Issue with article?

A HER3-targeting antibody–drug conjugate for leptomeningeal metastasis - Nature Medicine

|
By Carey Anders
| Nature Verified
The phase 2 TUXEDO-3 trial identifies the HER3-targeting antibody–drug conjugate patritumab deruxtecan as a promising new therapeutic option for patients with leptomeningeal metastasis from solid tumors. Enjoying our latest content? Login or create an account to continue Access the most recent journalism from Nature's award-winning team Explore the latest features & opinion covering groundbreaking research or References Ozair, A. et al. Nat. Rev. Clin. Oncol. 22, 134–154 (2025).
Open in Who Shared Issue with article?

Impact of systemic disease on CNS disease control after stereotactic radiosurgery to breast cancer brain metastases (The SYBRA Study) - npj Breast Cancer

|
By Alex Schick, Myla S. Strawderman, Sarah L. Sammons, Carey Anders
| Nature Verified
Abstract The objective of the study is to assess impact of systemic disease (SD) status on overall survival and brain metastasis (BM) control, adopting a novel landmark approach to categorize SD among breast cancer (BC) patients. This single institution retrospective study included BCBM patients who have received stereotactic radiosurgery (SRS) to brain.
Open in Who Shared Issue with article?
See all 44 licensed articles (51 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified